Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions. Read More
Bristol-Myers Squibb (BMY) presents a value investment case, trading at a deep discount with strong earnings power and a high dividend amid near-term challenges.
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the 67th American Society of Hematology (ASH) Annual Meeting, representing exciting advancements in the company’s next-generation hematology portfolio.
Bristol-Myers Squibb (BMY) offers a strong 5.4% dividend yield, backed by a history of reliable payments, robust profitability, and a sound financial position for income investors.
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025.
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers, making them crucial for insurers focused on the ACA marketplace. An extension would likely support sustained enrollment, securing a key revenue stream for these companies.
Bristol Myers Squibb (NYSE: BMY) today announced that, following the conclusion of the American Society of Hematology (ASH) Annual Meeting and Exposition, the company will hold a virtual investor event on Thursday, December 11, 2025, to highlight key Hematology programs.
The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have commanded significant attention with their pronounced stock swings. As of November 18, 2025, both companies find themselves at pivotal junctures, with
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the accepted amounts and pricing terms of the previously announced tender offers to purchase for cash its outstanding notes listed in the tables below.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the early participation results, as of 5:00 p.m. (New York City time) on November 17, 2025, (the “Early Tender Deadline”) of the previously announced tender offers to purchase for cash its outstanding notes listed in the tables below. Bristol Myers Squibb also announced that it is (i) decreasing the maximum aggregate purchase price of the Pool 1 Notes (as defined below) it will accept for purchase from the previously announced amount of $4,000,000,000 to an amount sufficient (the “Amended Pool 1 Maximum”) to accept for purchase all Pool 1 Notes that were validly tendered and not validly withdrawn prior to the Early Tender Deadline and (ii) increasing the maximum aggregate purchase price of the Pool 2 Notes (as defined below) it will accept for purchase from the previously announced amount of $3,000,000,000 to an amount sufficient (the “Amended Pool 2 Maximum”) to accept for purchase all Pool 2 Notes with an acceptance priority level at 1 through 4 (as set forth in the second table below) that were validly tendered and not validly withdrawn prior to the Early Tender Deadline as well as up to $250,000,000 in principal amount of Bristol Myers Squibb’s 5.900% Notes due 2033 (the “2033 Notes”). All other terms and conditions of the tender offers as previously announced in the Offer to Purchase, as amended and supplemented hereby, remain unchanged.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
